|
|
|
|
Fewer platelets could be used for some cancer and bone-marrow transplantation patients
Reducing platelet transfusions, and lowering the threshold on when to administer transfusions could help address frequent shortages in platelet supplies, said Dr.Victor Aquino, associate professor of pediatrics and an author of the study appearing in The New...
|
|
|
Irritable Bowel Syndrome patients not at more risk of colon cancer, polyps
Patients with irritable bowel syndrome are at no greater risk of having polyps, colon cancer or s than healthy people undergoing colonoscopies, according to new research published in the American Journal of Gastroenterology.'Patients and doctors get nervous...
|
|
|
Non-constipated IBS patients not at high risk for colonoscopy abnormalities
Clinical Last Updated: 2010-03-12 14:34:17 -0400 (Reuters Health) By David Douglas NEW YORK (Reuters Health) - Patients with non-constipated irritable bowel syndrome (IBS) have the same risk as healthy controls for structural abnormalities on colonoscopy,...
|
|
|
Piper Jaffray Initiates Coverage on Amgen (AMGN) with a Neutral; Anemia Headwinds Remain
Piper Jaffray initiates coverage on Amgen Inc.(Nasdaq: AMGN) with a Neutral rating. Price target $62. Piper analyst says, "We expect presentation of denosumab Phase III prostate cancer data at the ASCO (June 4-8) to confirm the drug's blockbuster...
|
|
|
Evotec to Screen for Hits against Active Biotech Immune Disorder and Cancer Target
Collaborations & Agreements GEN News Highlights GEN News Highlights Evotecsigned a high-throughput screening agreement with Active Biotech.The company is tasked with identifing and validating novel hits against an Active Biotech target involved in...
|
|
|
Affymax(R) Receives $5 Million Milestone Payment On Initiation Of Phase 3 Clinical Trials For Hematide In Japan
Affymax, Inc.(Nasdaq: AFFY) today announced that it has received a $5 million development milestone payment from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize Hematide, Affymax's...
|
|
|
Affymax gets $5mn milestone payment from Takeda
American pharma company Affymax has received a $5 million development milestone payment from Japan's Takeda Pharmaceutical.The payment is part of exclusive global agreement between the companies to develop and commercialize Hematide, Affymax's...
|
|
|
Ligand Announces Approval for Revolade in Europe
Ligand Pharmaceuticals Incorporated LGND Revolade was submitted for approval in Europe in December 2008, and received a positive opinion from the European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) in December 2009.European...
|
|
|
Lab Notes: IBS Not Always Indicative of Polyps, Cancer; Is Hooping the Next Exercise Craze?
On our Lab Notes page CalorieLabs editors select and rank the days essential health news items in real time.Readers can suggest, vote and comment on items. Below are brief summaries of yesterdays (March 11, 2010) Lab Notes items. To see todays items,...
|
|
|
FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosi
WOODCLIFF LAKE, N.J.The new outpatient dosing option provides physicians and patients with the flexibility of a dosing regimen with a reduced infusion time. Dacogen is the only hypomethylating agent approved for a five-day dosing regimen. The new regimen...
|
|
|
Management of Chronic Kidney Disease: What is the Evidence
Brosnahan G et al.In this article the authors discuss blood pressure goals for patients with CKD, the role of reninangiotensin system blocking agents for blood pressure control and proteinuria reduction, and the evidence for treatment recommendations of...
|
|
|
Few cancer and bone-marrow transplantation patients may gain from lesser platelets
Cancer is an incapacitating and life-threatening disease.Scientists seem to be developing new ways to effectually treat cancer. A new study from UT Southwestern Medical Center and 28 other institutions claims that doctors could carefully lower the platelet...
|
|
|
Critical Care in Obstetrics
In spite of great advances in the medical field and improved quality of healthcare available in our country, the maternal mortality in India is very high (437 deaths per 1, 00,000 live births).Anemia, haemorrhage sepsis and toxemia of pregnancy are the...
|
|
|
10 Biotech Stocks On the Line
BOSTON (TheStreet) -- Shares of InterMune(ITMN) are up almost 180% since last Friday.For investors who owned the drug company's stock last week, that means their investment more than doubled in value in just four trading sessions. Only in biotech can such...
|
|
|
Affymax Receives $5 Million Milestone Payment on Initiation of Phase 3 Clinical Trials for Hematide in Japan
PALO ALTO, Calif.-- (BUSINESS WIRE) -- Affymax, Inc.(Nasdaq: AFFY) today announced that it has received a $5 million development milestone payment from Takeda Pharmaceutical Company as part of the companies exclusive global agreement to develop and...
|
|
|
WinRho SDF (Rho(D) Immune Globulin Intravenous (human): Risk of intravascular hemolysis
Audience: Hematological healthcare professionals [Posted 03/10/2010] Cangene, Baxter and FDA notified healthcare professionals that cases of intravascular hemolysis (IVH) and its complications, including fatalities, have been reported in patients treated for...
|
|
|
Affymax receives $5M payment for drug development
Biotechnology company Affymax Inc.has received a $5 million milestone payment from Takeda Pharmaceutical Co. for the development of a potential anemia treatment. Affymax said Wednesday that Takeda issued the payment for the startup of late-stage...
|
|
|
Gastric bypass surgery increases risk of kidney stones, researchers report
Physicians may be able to safely lower the platelet dosage in transfusions for cancer and bone-marrow transplant patients without risking increased bleeding, according to new research involving UT Southwestern Medical Center and 28 other medical institutions?
|
|
|
Takeda pays Affymax $5 million for anemia drug's milestone
Affymax said it secured a milestone fee of $5 million from Takeda Pharmaceutical Takeda pays Affymax $5 million for anemia drug's milestone.
|
|
|
Fewer Platelets Could Be Used For Some Cancer And Bone-Marrow Transplantation Patients, Helping Alleviate Shortages
Physicians may be able to safely lower the platelet dosage in transfusions for cancer and bone-marrow transplant patients without risking increased bleeding, according to new research involving UT Southwestern Medical Center and 28 other medical institutions.
|
|
|
Management of Cancer Patients in ICU
Management of cancer patients in a critical care set-up is a challenging task.These patients are different from our regular ICU patients such that they may have undergone chemotherapy and/ or radiotherapy or a major debilitating surgery. ICU care is given...
|
|
|
Platelet dosage can be lowered in transfusions for cancer and bone-marrow transplant patients
Physicians may be able to safely lower the platelet dosage in transfusions for cancer and bone-marrow transplant patients without risking increased bleeding, according to new research involving UT Southwestern Medical Center and 28 other medical institutions.
|
|
|
Dialysis questions come on World Kidney Day
Question: My 71-year-old father has been recently diagnosed with chronic kidney disease and will eventually need to receive dialysis.Could you explain what is involved with dialysis and what options are available for his treatment? I hope the best for your...
|
|
|
Fewer platelets could be used for some cancer and bone-marrow transplantation patients
ScienceDaily (Mar.10, 2010) Physicians may be able to safely lower the platelet dosage in transfusions for cancer and bone-marrow transplant patients without risking increased bleeding, according to new research involving UT Southwestern Medical Center and...
|
|
|
Amgen Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new market report released
Refer to a friend 2010-03-10 22:49:02 - Amgen Inc.- Pharmaceuticals & Healthcare - Deals and Alliances Profile - a new market research report on companiesandmarkets.com Amgen Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile is an...
|
